Journals / Viral Hepatitis Journal / 2013 / Cilt: 19 - Sayı: 2

Pegile interferon + Ribavirin Tedavisi Alan Kronik Hepatit C’li 219 Olgunun Değerlendirilmesi

Evaluation of 2 19 Patients with Chronic Hepatitis C Receiving Pegylated Interferon + Ribavirin Treatment

Pages
71–75
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Ribavirin plus peginterferon alpha-2a or peginterferon alpha-2b were comparable outcomes in patients with CHC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In chronic hepatitis C (CHC) treatment, consensus guidelines recommend the use of either pegylated interferon (PEG-IFN) alfa 2a(40 KD), or PEG-IFN alfa 2b(12 KD) both plus ribavirin for treatment of chronic hepatitis C virus (HCV) infection.
📊
Key Findings & Data:Materials and Methods: A total of 219 treatment naïve or relapser (n=8), HCV RNA positive patients with CHC were assigned to once-weekly peginterferon 2a (180 µg, group PEG-A, n=115) or peginterferon 2b (1.5 µg/kg, group PEG-B, n=104) plus ribavirin (RBV) (800-1200 mg/day) for 48 weeks.
💡
Conclusion & Impact:Conclusion: Ribavirin plus peginterferon alpha-2a or peginterferon alpha-2b were comparable outcomes in patients with CHC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In chronic hepatitis C (CHC) treatment, consensus guidelines recommend the use of either pegylated interferon (PEG-IFN) alfa 2a(40 KD), or PEG-IFN alfa 2b(12 KD) both plus ribavirin for treatment of chronic hepatitis C virus (HCV) infection. The aim of this study was to evaluate treatments of CHC in our patients retrospectively. Materials and Methods: A total of 219 treatment naïve or relapser (n=8), HCV RNA positive patients with CHC were assigned to once-weekly peginterferon 2a (180 µg, group PEG-A, n=115) or peginterferon 2b (1.5 µg/kg, group PEG-B, n=104) plus ribavirin (RBV) (800-1200 mg/day) for 48 weeks. End of treatment response (ETR) and sustained virological response (SVR) were defined, respectively, as a negative qualitative HCV RNA level at the end of the treatment and after 24 weeks of untreated follow up. Results: End-of-treatment response (ETR) was obtained in 103 patients (92%) in PEG A group and 87 patients (86.1%) in group PEG B (p=0.171). SVR was 73.7% (n=157) in all of patients. This rate was 76.8 % (86/115) in group PEG A, and 70.3% (71/104) in group PEG B (p=0.283). SVR rates were not significantly different between two PEG IFN groups. Patients in groups PEG A discontinued treatment 4 (4.3%) and 8 (7.7%) in group PEG B respectively. There was no stastically difference in treatment discontinuation rate between groups (p=0.296). SVR was decreased with advanced age in both groups. Conclusion: Ribavirin plus peginterferon alpha-2a or peginterferon alpha-2b were comparable outcomes in patients with CHC.

Özet

Amaç: Kronik hepatit C (KHC)tedavisinde standart protokol pegile interferon (PEG-IFN) alfa 2a(40 KD), veya PEG-IFN alfa 2b(12 KD) ve ribavirin kombinasyonudur. Çalışmamızda kronik hepatit C’li hastalarımızın tedaviye yanıtlarının retrospektif olarak değerlendirilmesi amaçlandı. Gereç ve Yöntemler: 48 hafta süresince haftada bir kez peginterferon 2a (180 µg, grup PEG- A, n:115) veya peginterferon 2b (1,5 µg/kg ,grup PEG-B, n:104) ve ribavirin (800-1200 mg/gün) kombinasyon tedavisi uygulanan naiv veya relapser (n:8) toplam 219 HCV RNA pozitif KHC’li hasta değerlendirildi. Erken virolojik yanıt (tedavinin 12. haftasında serum HCV-RNA’nın negatif olması veya >2 log düşüş), Tedavi sonu yanıt (tedavi sonunda HCV_RNA’nın negatif olması),Kalıcı virolojik yanıt (tedavi sonlanmasını takiben 24. haftada HCV_RNA’nın negatif olması ) oranları değerlendirildi. Bulgular: Tedavi sonu yanıt oranı PEG A grubunda %92 (n:103), PEG B grubunda ise %86,1(n: 87) idi. (p=0,171). Kalıcı virolojik yanıt tüm hastalarda %73,7 (n=157) ; PEG A grubunda %76,8 ( 86/115) , PEG B grubunda ise % 70,3 (71/104) olarak tespit edildi. Her iki PEG IFN grubu arasında kalıcı virolojik yanıt oranları açısından anlamlı fark yoktu (p=0,283). PEG A grubundan 4 (% 4,3) PEG B grubundan ise 8 (%7,7) hastada tedavinin kesilmesi gerekti.Ancak tedavinin kesilmesi açısından her iki grup arasında istatistiki anlamlı fark yoktu. (p=0,296) Sonuç: KHC hastalarında ribavirin ile kombine olarak kullanılan peginterferon alfa-2a ve peginterferon alfa-2b tedaviye yanıt açısından kıyaslanabilir bulunmuştur.

🔖

Cite This Article

AYKIN, N., ÇAĞLAN, F. Ç., NAZ, H., KORKMAZ, P., US, T. (2013). Pegile interferon + Ribavirin Tedavisi Alan Kronik Hepatit C’li 219 Olgunun Değerlendirilmesi. Viral Hepatitis Journal, Cilt: 19 - Sayı: 2, 71–75. https://ajindex.com/articles/332765

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. World Health Organization. HepatitisC.2010 http://www.who. int/csr/disease/hepatitis/ whocdscsrlyo2003/en/index.html. Arrival date,
  2. Mallet V, Vallet-Pichard A, Pol S. New trends in hepatitis C management. Presse Med. 2010; 39(4): 446-51
  3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009 Apr;49(4):1335-74
  4. Ersöz G.Treatment of Hepatitis C. Turkiye Klinikleri J Gastroenterohepatol-Special Topics. 2010; 3(1): 96-102
  5. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010; 40(1): 8-13
  6. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschênes M. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol. 2007; (Suppl): 25-34
  7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 22; 358(9286):958-65
  8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr,et at. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82
  9. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P,et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55
  10. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010; 70(2): 147-65
  11. Gonzalez SA, Keeffe EB. Management of chronic hepatitis C treatment failures: role of consensus interferon. Biologics. 2009; 3: 141-50
  12. Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004; 350(22): 2265-71
  13. Garg G, Kar P. Manage